Susan Baker
Beverly Hills, CANPI 1912901448
Payments from drug & device makers
Across 671 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- UCB, Inc.$2K
- Johnson & Johnson$2K
- Pfizer$1K
- GSK$913
- plus $4K from 32 others
What the payments were for
- Food & beverage$14,28299%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 125 | $2,671 |
| AbbVie | 88 | $1,917 |
| UCB, Inc. | 65 | $1,687 |
| Johnson & Johnson | 80 | $1,637 |
| Pfizer | 50 | $1,073 |
| GSK | 48 | $913 |
| Lilly USA, LLC | 32 | $715 |
| Mallinckrodt Hospital Products Inc. | 22 | $488 |
| Novartis | 15 | $306 |
| AstraZeneca | 14 | $280 |
| Mallinckrodt Enterprises LLC | 12 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $220 |
| Bristol Myers Squibb | 21 | $212 |
| Merck | 11 | $195 |
| Sanofi | 9 | $190 |
| Radius Health, Inc. | 7 | $188 |
| Novo Nordisk | 7 | $163 |
| Bausch Health US, LLC | 6 | $135 |
| Aurinia Pharma U.S., Inc. | 5 | $133 |
| E.r. Squibb & Sons, L.L.C. | 8 | $128 |
| Bioventus LLC | 4 | $104 |
| AMAG Pharmaceuticals, Inc. | 3 | $92 |
| Boehringer Ingelheim | 3 | $89 |
| ANI Pharmaceuticals, Inc. | 3 | $80 |
| Hikma Pharmaceuticals USA | 3 | $58 |
| Janssen Scientific Affairs, LLC | 2 | $55 |
| Eisai Inc. | 3 | $53 |
| Shield Therapeutics Inc | 2 | $49 |
| Organon | 3 | $42 |
| Fidia Pharma USA Inc. | 1 | $41 |
| IBSA Pharma Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 1 | $38 |
| Sobi, Inc | 1 | $34 |
| Genentech USA, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Exact Sciences | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $208,598 |
| RybelsusSemaglutide | 13 | $10,872 |
| Hydroxychloroquine Sulfate | 37 | $1,885 |
| SynthroidLevothyroxine Sodium | 29 | $1,646 |
| Cevimeline Hcl | 14 | $1,463 |
| Levothyroxine Sodium | 74 | $741 |
| MethotrexateMethotrexate Sodium | 36 | $591 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $586 |
| Metformin Hcl ErMetformin Hcl | 67 | $508 |
| Atorvastatin Calcium | 37 | $371 |
| Metformin Hcl | 30 | $278 |
| Gabapentin | 24 | $260 |
| Zolpidem Tartrate | 19 | $222 |
| Metoprolol Succinate | 25 | $186 |
| Prednisone | 26 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $163 | $10,87213 claims |
| AbbVieSynthroid | $1,917 | $1,64629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.